参考文献/References:
[1] Oeffinger KC,Mertens AC,Sklar CA,et al. Chronic health conditions in adult survivors of childhood cancer[J]. N Engl J Med,2006,355(15):1572-1582.
[2] Essa H,Wright DJ,Dobson R,et al. Chemotherapy-induced arrhythmia-underrecognized and undertreated[J]. Am J Med,2021,134(10):1224-1231.
[3] Fu D,Calvo JA,Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents[J]. Nat Rev Cancer,2012,12(2):104-120.
[4] Phillips GL,Meisenberg B,Reece DE,et al. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan:a phase I study[J]. Biol Blood Marrow Transplant,2004,10(7):473-483.
[5] Dhesi S,Chu MP,Blevins G,et al. Cyclophosphamide-induced cardiomyopathy:a case report,review,and recommendations for management[J]. J Investig Med High Impact Case Rep,2013,1(1):2324709613480346.
[6] Raja W,Mir MH,Dar I,et al. Cisplatin induced paroxysmal supraventricular tachycardia[J]. Indian J Med Paediatr Oncol,2013,34(4):330-332.
[7] Quezado ZM,Wilson WH,Cunnion RE,et al. High-dose ifosfamide is associated with severe,reversible cardiac dysfunction[J]. Ann Intern Med,1993,118(1):31-36.
[8] Gottdiener JS,Appelbaum FR,Ferrans VJ,et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy[J]. Arch Intern Med,1981,141(6):758-763.
[9] Henriksen PA. Anthracycline cardiotoxicity:an update on mechanisms,monitoring and prevention[J]. Heart,2018,104(12):971-977.
[10] Kilickap S,Barista I,Akgul E,et al. Early and late arrhythmogenic effects of doxorubicin[J]. South Med J,2007,100(3):262-265.
[11] Turakhia MP,Hoang DD,Zimetbaum P,et al. Diagnostic utility of a novel leadless arrhythmia monitoring device[J]. Am J Cardiol,2013,112(4):520-524.
[12] Chong JH,Ghosh AK. Coronary artery vasospasm induced by 5-fluorouracil:proposed mechanisms,existing management options and future directions[J]. Interv Cardiol,2019,14(2):89-94.
[13] Ng M,Cunningham D,Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)[J]. Eur J Cancer,2005,41(11):1542-1546.
[14] Hilmi M,Ederhy S,Waintraub X,et al. Cardiotoxicity associated with gemcitabine:literature review and a pharmacovigilance study[J]. Pharmaceuticals(Basel),2020,13(10):325.
[15] Essa H,Dobson R,Lip GYH. Chemotherapy induced arrhythmias[J]. J Cardiovasc Pharmacol,2022,80(4):531-539.
[16] Roca E,Bruera E,Politi PM,et al. Vinca alkaloid-induced cardiovascular autonomic neuropathy[J]. Cancer Treat Rep,1985,69(2):149-151.
[17] Xiao Y,Yin J,Wei J,et al. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer:a systematic review and meta-analysis[J]. PLoS One,2014,9(1):e87671.
[18] Eckschlager T,Plch J,Stiborova M,et al. Histone deacetylase inhibitors as anticancer drugs[J]. Int J Mol Sci,2017,18(7):1414.
[19] Herrmann J. Adverse cardiac effects of cancer therapies:cardiotoxicity and arrhythmia[J]. Nat Rev Cardiol,2020,17(8):474-502.
[20] Petrini I,Lencioni M,Ricasoli M,et al. PhaseⅡtrial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma[J]. Cancer Chemother Pharmacol,2012,69(3):773-780.
[21] Stein-Merlob AF,Rothberg MV,Holman P,et al. Immunotherapy-associated cardiotoxicity of immune checkpoint inhibitors and chimeric antigen receptor T cell therapy:diagnostic and management challenges and strategies[J]. Curr Cardiol Rep,2021,23(3):11.
[22] Mir H,Alhussein M,Alrashidi S,et al. Cardiac complications associated with checkpoint inhibition:a systematic review of the literature in an important emerging area[J]. Can J Cardiol,2018,34(8):1059-1068.
[23] Johnson DB,Balko JM,Compton ML,et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med,2016,375(18):1749-1755.
[24] Brudno JN,Kochenderfer JN. Kochenderfer toxicities of chimeric antigen receptor T cells:recognition and management[J]. Blood,2016,127(26):3321-3330.
[25] S?awiński G,Wrona A,D?browska-Kugacka A,et al. Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung cancer:a review[J]. Int J Mol Sci,2020,21(19):7195.
[26] Shalata W,Abu-Salman A,Steckbeck R,et al. Cardiac toxicity associated with immune checkpoint inhibitors:a systematic review[J]. Cancers(Basel),2021,13(20):5218.
[27] Siri-Angkul N,Chattipakorn SC,Chattipakorn N. The mechanistic insights of the arrhythmogenic effect of trastuzumab[J]. Biomed Pharmacother,2021,139:111620.
[28] Truong SR,Barry WT,Moslehi JJ,et al. Evaluating the utility of baseline cardiac function screening in early-stage breast cancer treatment[J]. Oncologist,2016,21(6):666-670.
[29] Zhou X,Yu J,Wang W,et al. A phaseⅠdose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients[J]. Springerplus,2015,4:803.
[30] Piotrowski G,Gawor R,Stasiak A,et al. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2—A prospective study [J]. Arch Med Sci,2012,8(2):227-235.
[31] Krause DS,van Etten RA. Tyrosine kinases as targets for cancer therapy[J]. N Engl J Med,2005,353(2):172-187.
[32] Wu P,Nielsen TE,Clausen MH. Small-molecule kinase inhibitors:an analysis of FDA-approved drugs[J]. Drug Discov Today,2016,21(1):5-10.
[33] Abu Rmilah AA,Lin G,Begna KH,et al. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors[J]. Int J Cancer,2020,147(11):3160-3167.
[34] Cheng M,Yang F,Liu J,et al. Tyrosine kinase inhibitors-induced arrhythmias:from molecular mechanisms,pharmacokinetics to therapeutic strategies[J]. Front Cardiovasc Med,2021,8:758010.
[35] Ye JZ,Hansen FB,Mills RW,et al. Oncotherapeutic protein kinase inhibitors associated with pro-arrhythmic liability[J]. JACC CardioOncol,2021,3(1):88-97.
[36] Shah RR,Morganroth J,Shah DR. Cardiovascular safety of tyrosine kinase inhibitors:with a special focus on cardiac repolarisation(QT interval)[J]. Drug Saf,2013,36(5):295-316.
[37] Thill M,Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer[J]. Ther Adv Med Oncol,2018,10:1758835918793326.
[38] Bellet M,Ahmad F,Villanueva R,et al. Palbociclib and ribociclib in breast cancer:consensus workshop on the management of concomitant medication[J]. Ther Adv Med Oncol,2019,11:1758835919833867.
[39] Lyon AR,López-Fernández T,Couch LS,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association(EHA),the European Society for Therapeutic Radiology and Oncology(ESTRO) and the International Cardio-Oncology Society(IC-OS)[J]. Eur Heart J Cardiovasc Imaging,2022,23(10):e333-e465.
[40] Rossello X,Dorresteijn JA,Janssen A,et al. Risk prediction tools in cardiovascular disease prevention:a report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology(EAPC) in collaboration with the Acute Cardiovascular Care Association(ACCA) and the Association of Cardiovascular Nursing and Allied Professions(ACNAP)[J]. Eur J Cardiovasc Nurs,2019,18(7):534-544.
[41] Farmakis D,Parissis J,Filippatos G. Insights into onco-cardiology:atrial fibrillation in cancer[J]. J Am Coll Cardiol,2014,63(10):945-953.
[42] Fradley MG,Beckie TM,Brown SA,et al. Recognition,prevention,and management of arrhythmias and autonomic disorders in cardio-oncology:a scientific statement from the American Heart Association[J]. Circulation,2021,144(3):e41-e55.
[43] Priori SG,Blomstr?m-Lundqvist C,Mazzanti A,et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology(ESC). Endorsed by:Association for European Paediatric and Congenital Cardiology(AEPC)[J]. Eur Heart J,2015,36(41):2793-2867.
[44] Al-Khatib SM,Stevenson WG,Ackerman MJ,et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. Heart Rhythm,2018,15(10):e73-e189.
[45] Ishibashi H,Wakejima R,Asakawa A,et al. Postoperative atrial fibrillation in lung cancer lobectomy-analysis of risk factors and prognosis[J]. World J Surg,2020,44(11):3952-3959.
[46] Murthy SC,Law S,Whooley BP,et al. Atrial fibrillation after esophagectomy is a marker for postoperative morbidity and mortality[J]. J Thorac Cardiovasc Surg,2003,126(4):1162-1167.
[47] Guha A,Fradley MG,Dent SF,et al. Incidence,risk factors,and mortality of atrial fibrillation in breast cancer:a SEER-Medicare analysis[J]. Eur Heart J,2022,43(4):300-312.
相似文献/References:
[1]赵靖华,综述,尚美生,等.衰老与心律失常[J].心血管病学进展,2016,(2):121.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.006]
ZHAO Jinghua,SHANG Meisheng,YAO Yan.Aging and Arrhythmias[J].Advances in Cardiovascular Diseases,2016,(5):121.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.006]
[2]娄奇,李为民.CaV1.2在心律失常中作用的研究进展[J].心血管病学进展,2019,(6):919.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.020]
LOU Qi,LI Weimin.CaV1.2 in Arrhythmias[J].Advances in Cardiovascular Diseases,2019,(5):919.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.020]
[3]李如意 刘延俊 杜荣品.心力衰竭时β3-肾上腺素能受体与心律失常的研究进展[J].心血管病学进展,2020,(1):51.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.014]
LI Ruyi,LIU Yanjun,DU Rongpin.β3-adrenergic Receptors and Arrhythmia in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(5):51.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.014]
[4]王爱荣,江高峰.放射治疗致心血管疾病的研究进展[J].心血管病学进展,2020,(3):242.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.007]
WANG Airong,JIANG Gaofeng.Radiation-induced Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(5):242.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.007]
[5]阿依尼尕尔·马木提 周贤惠.光遗传学技术在心律失常研究中的应用及进展[J].心血管病学进展,2020,(7):687.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.004]
Ayinigaer·Mamuti,ZHOU Xianhui.Application and Progress of Optogenetics in Study of Cardiac Arrhythmias[J].Advances in Cardiovascular Diseases,2020,(5):687.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.004]
[6]程家元 殷跃辉.沙库巴曲缬沙坦在心血管疾病中的临床应用与展望[J].心血管病学进展,2020,(9):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
CHENG Jiayuan YIN Yuehui.Clinical Application and Prospect of Sacubitril Valsartan in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(5):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
[7]查克岚 叶强.心电图成像在心律失常诊治中的研究进展[J].心血管病学进展,2020,(9):930.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.011]
ZHA Kelan,YE Qiang.Electrocardiographic Imaging in Arrhythmia Diagnosis and Treatment[J].Advances in Cardiovascular Diseases,2020,(5):930.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.011]
[8]袁佳栎 王群山.人工智能在心律失常诊断中的前景与挑战[J].心血管病学进展,2020,(10):999.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.001]
YUAN JialiWANG Qunshan.Prospects and Challenges of Arrhythmia Diagnosis by Artificial Intelligence[J].Advances in Cardiovascular Diseases,2020,(5):999.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.001]
[9]林晶 吉庆伟 刘伶.致心律失常性心肌病的研究进展[J].心血管病学进展,2020,(12):1247.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.006]
LING JingJI Qingwei,LIU Lin.Arrhythmogenic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(5):1247.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.006]
[10]李翠兰 刘文玲 高元丰.先天性与获得性长QT综合征诊断治疗现状[J].心血管病学进展,2021,(5):385.[doi:10.16806/j.cnki.issn.1004-3934.2021.0.001]
LI Cuilan,LIU Wenling,GAO Yuanfeng.Diagnostic and Therapeutic Status for Congenital and Acquired Long QT Syndrome[J].Advances in Cardiovascular Diseases,2021,(5):385.[doi:10.16806/j.cnki.issn.1004-3934.2021.0.001]